Telix Pharmaceuticals Discusses Innovations in PSMA PET CT Imaging for Prostate Cancer

Experts share physician perspectives on advancements in prostate cancer imaging technology

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Telix Pharmaceuticals hosted a webinar featuring a panel discussion with leading medical experts to discuss physician perspectives on innovations in PSMA PET CT imaging for prostate cancer. The panel included Rodney Hicks, Professor of Medicine at the University of Melbourne and Monash University, and Dr. Paul Yonover, Chief Data Officer and Director of Clinical Navigation at UroPartners, as well as Darren Patti, Telix's Group Chief Operating Officer.

Why it matters

PSMA PET CT imaging is an emerging technology that is transforming the way prostate cancer is detected and managed. Understanding physician perspectives on these advancements is crucial as the medical community works to improve outcomes for prostate cancer patients.

The details

The webinar featured a moderated panel discussion where the experts shared insights on the latest innovations in PSMA PET CT imaging and how these technologies are impacting clinical practice. Topics covered included the benefits of PSMA PET CT over traditional imaging methods, the role of data and analytics in guiding treatment decisions, and the potential for these advancements to lead to earlier detection and more personalized care for prostate cancer patients.

  • The webinar was held on March 4, 2026.

The players

Rodney Hicks

Professor of Medicine at the University of Melbourne and Monash University, Founder and Executive Chairman and Chief Medical Officer at the Melbourne Theranostic Innovation Center.

Dr. Paul Yonover

Chief Data Officer and Director of Clinical Navigation at UroPartners, a division of The Specialty Alliance, Chief of Urology at Ascension Saint Joseph Hospital in Chicago.

Darren Patti

Telix Pharmaceuticals' Group Chief Operating Officer.

Got photos? Submit your photos here. ›

What they’re saying

“Today's format will be a moderated panel discussion hosted by Dr. David Cade, MD, Chief Medical Officer -- Group Chief Medical Officer at Telix. I'm very pleased to welcome our speakers.”

— Kyahn Williamson, Senior Vice President of Corporate Communications & Investor Relations (seekingalpha.com)

The takeaway

This webinar highlights the growing importance of PSMA PET CT imaging in the diagnosis and management of prostate cancer. By bringing together leading experts to share their perspectives, Telix Pharmaceuticals is helping to advance the medical community's understanding of these innovative technologies and their potential to improve patient outcomes.